Development

Articles

Data and science must guide FDA in making pressure-filled COVID-19 vaccine and therapy approval decisions.

Navigating Uncharted Waters

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Therapies for early and late treatment and passive immunization of COVID-19 are needed and can be developed using antibodies from recovered patients.

Plasma-Based Antibody Therapies Battle Against COVID-19

With the acquisition, Orgenesis will combine TamirBio’s ranpirnase antiviral platform with its Bioxome technology.

Orgenesis to Acquire Tamir Biotechnology for Broad Spectrum Antiviral Platform

As a result of the rising use and development of biological drugs, the biopharma industry is witnessing an increase in the adoption of prefilled syringes.

On Point: Biologics Drive Growth in Pre-Filled Syringes

Contract service organizations can offer biopharma companies early insight into dangers that may hinder a drug’s later development.

Seeking Early Answers to Formulation Questions

The companies have entered into a global licensing and collaboration agreement to commercialize ReForm excipients used in biotherapeutic formulations.

MilliporeSigma and ReForm Collaborate on Excipient Commercialization

Editor of Pharmaceutical Technology Europe

Biologics raise unique formulation and development challenges, and industry is still on a learning curve to get the best out of these diverse and complex therapies.

Fresh Thinking in Biologic Drug Formulation

This study aims to use plant-leaf extract for the green synthesis of gold nanoparticles and to evaluate their antibacterial and antioxidant activity.

Therapeutic Potential of Green, Synthesized Gold Nanoparticles

The new Technology Excellence Center, located in Boston, MA, will further the company’s presence in the United States biopharma drug development landscape.

Stevanato Group Breaks Ground on New Technology Excellence Center

BASF launches digital solutions for the pharma industry during CPhI Worldwide 2019.